Fundamental Analysis of CELLECTAR BIOSCIENCES INC(NASDAQ:CLRB) stock

Fundamental Rating

CLRB gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. CLRB has a bad profitability rating. Also its financial health evaluation is rather negative. CLRB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CLRB has reported negative net income.

In the past year CLRB has reported a negative cash flow from operations.

In the past 5 years CLRB always reported negative net income.

In the past 5 years CLRB always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -314.51%, CLRB is not doing good in the industry: 94.37% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-314.51%
ROE	N/A
ROIC	N/A

ROA(3y)-170.62%

ROA(5y)-130.52%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLRB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CLRB has more shares outstanding

CLRB has more shares outstanding than it did 5 years ago.

CLRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -31.55, we must say that CLRB is in the distress zone and has some risk of bankruptcy.

CLRB has a Altman-Z score of -31.55. This is amonst the worse of the industry: CLRB underperforms 91.64% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-31.55

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CLRB has a Current Ratio of 0.81. This is a bad value and indicates that CLRB is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Current ratio value of 0.81, CLRB is not doing good in the industry: 91.81% of the companies in the same industry are doing better.

A Quick Ratio of 0.81 indicates that CLRB may have some problems paying its short term obligations.

CLRB has a Quick ratio of 0.81. This is amonst the worse of the industry: CLRB underperforms 91.30% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.81
Quick Ratio	0.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.65% over the past year.

EPS 1Y (TTM)27.65%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-10.91%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

CLRB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.84% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y43.17%

EPS Next 2Y34.14%

EPS Next 3Y27.15%

EPS Next 5Y25.84%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CLRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CLRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CLRB's earnings are expected to grow with 27.15% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y34.14%

EPS Next 3Y27.15%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CLRB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (5/2/2024, 1:45:20 PM)

3.355

+0.19 (+6.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap108.23M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-314.51%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.81
Quick Ratio	0.81
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)27.65%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y43.17%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CELLECTAR BIOSCIENCES INC (CLRB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens